(Posted By: Josi Creek)Biogen Idec (NASDAQ: BIIB) today issued the following statement regarding the United States (U.S.) Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. The U.S. FDA approval was granted on January 22, 2010.
AMPYRA will be marketed in the U.S by Acorda Therapeutics, Inc. (NASDAQ: ACOR). AMPYRA is an extended release tablet formulation of the investigational drug dalfampridine (4-aminopyridine and called fampridine outside the U.S.). Biogen Idec will commercialize fampridine as a prolonged release tablet in markets outside of the U.S.
Read the full story here.
